Vulvovaginal Candidiasis Treatment Market Size- By Drug Class, By Route of Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Global Vulvovaginal Candidiasis Treatment Market Overview:

According to SPER Market Research, the Global Vulvovaginal Candidiasis Treatment Market is estimated to reach USD 1.62 billion by 2032 with a CAGR of 4.61%.

The vagina and the tissues close to the vulva's opening are both impacted by vulvovaginal candidiasis, a yeast infection. Candida species are the culprit behind it. Intense itching, inflammation, a thick, white discharge, and other signs of the illness are present. A single dose of the antifungal medication or the use of antifungal creams can cure a mild infection, but more extensive infections need more time-consuming therapy. The size of the global market for vulvovaginal candidiasis treatments is anticipated to increase. An NCBI article claims that VVC is a frequent virus in women that affects millions of women annually all over the world. Rising illness burden, a strong growing pipeline with recent approvals of disease management medicines, and the introduction of novel pharmaceuticals like BREXAFEMME and VIVJOA are some of the main reasons propelling market growth.The rising prevalence of VVC disease, the approval of novel medications that can address unmet needs, and initiatives by the government and non-profit groups to raise awareness are some of the major drivers of business growth.

Impact of COVID-19 on the Global Vulvovaginal Candidiasis Treatment Market:

The global expansion of the new coronavirus has had a minor influence on the market for treating vulvovaginal candidiasis. Due to the increased prevalence of candidiasis among COVID-19 patients, there was a considerable demand for medications to treat vulvovaginal candidiasis. This is due to an increase in bloodstream infections and infections related with healthcare, particularly in patients who have been hospitalized to hospitals. The market for vulvovaginal candidiasis has quickly rebounded as a result of all these factors, and it is expected to keep expanding.

Scope of the Report:

• Market size available for years: 2019-2032

• Base year considered: 2021

• Forecast period: 2022-2032

• Segments covered: By Drug Class, By Route of Administration, By Distribution Channel

• Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

• Companies Covered: Astellas Pharma Inc., Basilea Pharmaceutica Ltd., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Grupo Ferrer International S.A., Mycovia Pharmaceuticals, Inc., Pfizer, Inc., Scynexis, Inc.

Global Vulvovaginal Candidiasis Treatment Market Segmentation:

• By Drug Class: Based on the Drug Class, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Clotrimazole, Fluconazole, Ketoconazole, Nystatin, Terbinafine, Terconazole, Others.

• By Route of Administration: Based on the Route of Administration, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Intravenous, Oral, Topical.

• By Distribution Channel: Based on the Distribution Channel, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

• By Region: The global industry was dominated by North America. The area is anticipated to continue to grow steadily during the projection period, maintaining its leadership position. High disease prevalence, rising patient awareness, rising healthcare costs, and the existence of significant players in the area can all be contributed to this dominance. The development of the regional market is also aided by new approvals, launches, and innovative government initiatives. Asia Pacific, on the other hand, is anticipated to experience the fastest growth rate during the anticipated years. The increased disease burden of VVC and rising testing rates are both responsible for the high growth rate. Positive developments include government healthcare coverage, increasing consumer awareness, and a desire to use medical services.